news
Nektar submits IND for NKTR-214 to treat solid tumours
8 October 2015 | By Victoria White
NKTR-214 is a CD122-biased immune-stimulatory cytokine that is designed to stimulate the expansion and maintenance of CD8-positive effector T-cells...
List view / Grid view
T cells
news
apceth and University of Cologne to join forces on combination cellular immunotherapies for cancer
10 July 2015 | By Victoria White
apceth is to partner with the University of Cologne to combine technologies and expertise, on the development of immunotherapies for solid tumours...
news
Didehydro-Cortistatin A reduces HIV reactivation rate
9 July 2015 | By Victoria White
Scientists have shown that didehydro-Cortistatin A reduces residual levels of HIV virus from dormant cells, establishing a near-permanent state of latency...
news
Celgene and Juno Therapeutics announce 10 year immunotherapy collaboration
30 June 2015 | By Victoria White
Celgene and Juno Therapeutics have entered into a global collaboration for the development and commercialisation of immunotherapies...
news
T cell exhaustion study has possible implications for cancer and antiviral therapies
4 June 2015 | By Victoria White
When the T cells of your immune system are forced to deal over time with cancer or a chronic infection, they can develop "T cell exhaustion"...
article
Immune checkpoint inhibitors: targets on the horizon
Immune checkpoint inhibitory antibodies have provided a great conceptual change in the field of immune-oncology. Rather than targeting the tumour directly, these novel drugs are aimed at preventing the interactions between the tumour and the immune system, which the cancer exploits to evade immune recognition...